SCHEMBL3089769

SCHEMBL3089769

Cc1ccc2c(c1C)NC(=O)C2(O)C1CCCCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 7/20 0.45
ALDH1A1 P00352 4/20 0.40
HSD17B10 Q99714 2/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPT P10636 2/20 0.35
BRD2 P25440 2/20 0.34
BRD3 Q15059 2/20 0.34
BRDT Q58F21 2/20 0.34
ATM Q13315 1/20 0.34
POLB P06746 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
APOBEC3A P31941 1/20 0.33
HTT P42858 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
RECQL P46063 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
IDO1 P14902 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3082149 1.00 BRD4 (0.45) BRD4ALDH1A1HSD17B10KMT2ASMN1; SMN2
SCHEMBL3082410 0.86 BRD4 (0.43) BRD4ALDH1A1HSD17B10KMT2ASMN1; SMN2
SCHEMBL3096345 0.86 BRD4 (0.43) BRD4ALDH1A1HSD17B10SMN1; SMN2BRD2
SCHEMBL3092409 0.86 BRD4 (0.43) BRD4ALDH1A1HSD17B10SMN1; SMN2BRD2
SCHEMBL3096095 0.86 BRD4 (0.43) BRD4ALDH1A1HSD17B10KMT2ASMN1; SMN2
SCHEMBL3096358 0.86 BRD4 (0.43) BRD4ALDH1A1HSD17B10KMT2ASMN1; SMN2
SCHEMBL3090110 0.86 BRD4 (0.43) BRD4ALDH1A1HSD17B10KMT2ASMN1; SMN2
SCHEMBL3080911 0.86 BRD4 (0.43) BRD4ALDH1A1HSD17B10SMN1; SMN2BRD2
SCHEMBL3088871 0.86 BRD4 (0.43) BRD4ALDH1A1HSD17B10KMT2ASMN1; SMN2
SCHEMBL3086066 0.86 BRD4 (0.43) BRD4ALDH1A1HSD17B10KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TOPOTARGET A/S (DK) 2010-09-09 US disclosed
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TOPOTARGET A/S (DK) 2010-09-09 US disclosed
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TOPOTARGET A/S (DK) 2010-09-09 US disclosed
EP-2139856-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE-COMPOUNDS Topotarget A/S (DK) 2010-01-06 EP disclosed
WO-2008129075-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE-COMPOUNDS TOPOTARGET A/S (DK) 2008-10-30 WO disclosed
WO-2008129075-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE-COMPOUNDS TOPOTARGET A/S (DK) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TPH2, TPH1, HTR2C BRD4 616/4885ALDH1A1 360/4885HSD17B10 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.